Boston Scientific (BSX) Long-Term Investments (2019 - 2020)

Boston Scientific (BSX) reported Long-Term Investments of $567.0 million for Q3 2020, up 21.41% sequentially from $467.0 million in Q2 2020.

Boston Scientific (BSX) Long-Term Investments (2019 - 2020) Analysis & Trends

Boston Scientific (BSX) has 2 years of Long-Term Investments data on file, last reported at $567.0 million in Q3 2020.

For the quarter ending Q3 2020, Long-Term Investments changed N/A year-over-year to $567.0 million; the trailing twelve-month figure through Sep 2020 stood at $567.0 million (changed N/A YoY), and the FY2019 full-year result was $458.0 million, changed N/A from the prior year.
Long-Term Investments grew to $567.0 million in Q3 2020, from $467.0 million in the prior quarter.
In the past five years, Long-Term Investments ranged from a high of $567.0 million in Q3 2020 to a low of $437.0 million in Q1 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn	1.09 Bn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn	-
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn	-
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn	-
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn	285.60 Mn
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn	-
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn	166.25 Mn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn	-
9	Smith & Nephew	25.80 Bn	25.22 Bn	-	121.00 Mn
10	Steris	20.59 Bn	20.16 Bn	697.10 Mn	-

Download Data